Microplastics contaminate salt, bottled water, and food packaging. Here are 12 evidence-based swaps to reduce your daily exposure.
The FDA approved the first oral GLP-1 pill for weight loss in December 2025. Here is what the clinical data shows about efficacy, side effects, and cost.
Medicare is covering Wegovy and Zepbound for weight loss at $50/month starting July 2026 through the GLP-1 Bridge program. Here is who qualifies and how to enroll.
SURMOUNT trial data shows tirzepatide produces 23% weight loss in postmenopausal women. HRT may enhance GLP-1 results by 35%.
Evidence-based guide covering skin retraction timelines, non-surgical treatments, body contouring surgery, and collagen-supporting nutrition for GLP-1 weight loss patients.
A meta-analysis of 18 trials found 5.63 kg average weight regain after stopping GLP-1 drugs, but real-world data from 188K patients shows 56% sustain some loss at 2 years.
FDA adverse event data links semaglutide to alopecia at 2.46x the expected rate. Most cases are telogen effluvium from rapid weight loss, and 95% resolve on their own.
From $1,349 list prices to $25 copays, GLP-1 drug costs depend on which programs you use. Here is what works now.
GLP-1 drugs like Ozempic and Wegovy increase gallbladder disease risk by up to 2.29x. A research-backed guide to the risks, warning signs, and prevention strategies.
The FDA approved semaglutide (Wegovy) as the first GLP-1 drug for MASH liver disease. The ESSENCE trial showed 62.9% of patients achieved disease resolution.
The FLOW trial cut kidney disease progression by 24% and death by 20%. Here is what the FDA approval means for the 37 million Americans with CKD.
Microplastics contaminate salt, bottled water, and food packaging.
Here are 12 evidence-based swaps to reduce your daily exposure.
The goal isn’t to be comfortable with change — it’s to be comfortable with one small change, on a schedule, held for a year.
We’re recording with NotebookLM. Expect a deep-dive and a short-form version of each issue’s best essays, delivered to your favorite podcast app when we launch.